ScaPho

Secukinumab (Scapho) Instructions
Generic name: Secukinumab
Trade name: Scapho
All names: Secukinumab, Cosentyx, Secukinumab, Cosentyx, Scapho, Secukinumab

Indications:
For the treatment of adult patients with moderate to severe plaque psoriasis who are indicated for systemic therapy or phototherapy.

Usage and dosage:
Cosentyx should be administered once a week at 150mg or 300mg in the first five weeks of 0, 1, 2, 3, and 4, and then 150mg or 300mg should be injected once a month. Because each psoriasis patient's weight and disease severity are different, some psoriasis patients are more suitable for a dosage of 150 mg. Please follow your doctor's advice for the specific dosage.
Before injecting Cosentyx, take out the Cosentyx injection from the refrigerator and place it in a clear to slightly opaque or yellowish solution for direct subcutaneous injection in an area without skin lesions within one hour. Psoriasis patients can use Kesenting on their own next time after being instructed by their doctor to use it because the operation is relatively simple.

Adverse reactions:
> 10%
Infection (28.7%)
Nasopharyngitis (11.4-12.3%)

1-10%
Diarrhea (2.6-4.1%)
URT infection (2.5-3.2%)
Rhinitis (1.4%)
Oral herpes ( 0.1-1.3%)
Pharyngitis (1-1.2%)
Urticaria (0.6-1.2%)
Rhinorrhea (0.3-1.2%)

Contraindications:
Allergies

Precautions:
May increase risk of infection; Consider use with caution in patients with a history of chronic infection or recurrent infection
Assess patients for tuberculosis (TB) infection before initiation; Do not administer active tuberculosis; In patients with latent tuberculosis, initiate antituberculous therapy before starting secukinumab therapy in patients with a history of latent or active tuberculosis, in whom an adequate regimen cannot be confirmed
May exacerbate Crohn's disease
Cases of allergic reactions and urticaria have been reported; If this occurs, immediately discontinue secukinumab and initiate treatment for anaphylaxis
Be aware of latex allergy; removable caps on Sensoready pens and prefilled syringes contain natural rubber
Vaccinations
Before starting treatment, consider completing all age-appropriate immunizations according to current immunization guidelines
Patients receiving secukinumab should not receive live vaccines Vaccine
Inactive vaccines received during a course of secukinumab may not elicit an immune response sufficient to prevent disease

Storage:
Store vials refrigerated at 2-8ºC (36-46ºF)
Keep in original carton protected from light until use
Do not freeze
To avoid blistering, do not shake
Contains no preservatives; Discard any unused portion
Reconstitute vial
After reconstitution, use solution immediately or store in refrigerator at 2-8ºC (36-46ºF) for 24 hours
Do not freeze
Allow to reach room temperature (15-30 minutes) before dosing
Contains no preservatives; Therefore, administer the drug within 1 hour after taking it out of the refrigerator

Mechanism of action:
Cosentyx (commonly known as secukinumab) is currently the first and only fully humanized biological agent that can specifically inhibit interleukin 17A (IL-17A). IL-17A is a core pathogenic factor involved in the inflammation and disease progression of psoriasis (PsO), arthropathic psoriasis (PsA) and ankylosing spondylitis (AS), and plays a cornerstone role in the pathogenesis7-10. IL-17A can be produced by both IL-23-dependent and IL-23-independent pathways and is produced by a variety of cells of the innate immune system (which can be triggered by mechanical stress) and the adaptive immune system. By acting directly on IL-17A from different sources, Cosentyx (commonly known as secukinumab) can inhibit this cornerstone cytokine.

Efficacy and Safety:
Novartis announced the latest phase III study data on the efficacy and safety of Cosentyx (commonly known as secukinumab) in the treatment of moderate to severe plaque psoriasis in Chinese patients. The Phase III study is a randomized, double-blind, placebo-controlled, international multi-center study lasting 52 weeks and enrolling 543 patients. What was released this time was the data on 441 Chinese patients in the study.
Data show that among all Chinese patients treated with Cosentyx (commonly known as secukinumab) 300 mg, 97.7% and 80.9% of patients achieved PASI 75 (i.e., a 75% improvement in the Psoriasis Area and Severity Index) and PASI 90 at week 12, respectively, and 87% of patients reached PASI 90 at week 16. Among patients treated with Cosentyx (commonly known as secukinumab) 150 mg, 87.8% and 66.4% achieved PASI 75 and PASI 901, respectively, at week 12.
“The data from this Chinese clinical trial are very promising, even better than some international data in terms of efficacy and safety.” Professor Zhang Jianzhong, former chairman of the Dermatology and Venereology Branch of the Chinese Medical Association, as the leader of this phase III research project, said: “This result may bring revolutionary changes to the treatment of psoriasis in China and will promote the overall transformation of China’s psoriasis treatment strategy. First of all, it will help to improve the overall treatment target, and is expected to increase the psoriasis treatment target from PASI 75 to PASI 90 or even PASI. 100; Secondly, this phase III study reflects the excellent safety profile of Cosentyx (commonly known as secukinumab). In the past, biological agents were only considered for use after phototherapy and systemic treatments were ineffective, but in the future this order is likely to be rewritten, and biological agents may become the first-line drugs for systemic treatment. This will allow more patients with moderate to severe psoriasis to receive better and safer treatment as early as possible. ”
A large amount of data accumulated in 100 clinical studies around the world has proven that 8 out of 10 patients can achieve clear or almost clear skin lesions through 16 weeks of Cosentyx (commonly known as secukinumab) treatment3. Patient response rates can be nearly 100% maintained for up to 5 years 4 . It is a fully human monoclonal antibody that neutralizes IL-17A. It shows rapid, long-lasting efficacy and safety in the treatment of moderate to severe psoriasis, joint psoriasis, and psoriasis in other parts of the body (scalp, palmoplantar, and fingernail psoriasis).